Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Glaucoma Treatment Market By Indication, By Drug Class, By Sales Channel, and Geography
Glaucoma Treatment Market size was valued at US$ 7.91 billion in 2022 and is projected to reach US$ 13.53 billion by 2029, growing at a CAGR of 6.98% from 2023 to 2029. Glaucoma is known as the silent thief of sight because most kinds of the disease generate no discomfort or symptoms until significant vision loss occurs. Glaucoma is a collection of eye illnesses that develop when the optic nerve, which transmits information from the eye to the brain, is damaged. The majority of cases are linked to ocular hypertension, a condition in which the pressure inside the eye is higher than normal, although it can also happen when the intraocular pressure is normal. If left untreated, it causes peripheral vision loss, which then progresses to permanent blindness. Glaucoma is the world's second largest cause of blindness. During normal eye exams, a tonometer is used to measure intraocular pressure (IOP). IOP should be less than 21 mmHg in most cases. Glaucoma treatment options include surgery, laser treatment, and medication, depending on the severity of the condition. The majority of eye drops are used to reduce IOP, which is the initial line of defence against glaucoma. Most people are casual about using eye drops correctly, and failing to take prescribed prescription is a primary cause of blindness. Glaucoma Treatment Market owing to rising prevalence of Glaucoma. For instance, WHO estimates that 4.5 million people are blind due to Glaucoma. In India, Glaucoma is the leading cause of irreversible blindness with at least 12 million people affected and nearly 1.2 million people blind from the disease. Moreover, around 90+ percent of the cases of the glaucoma are undiagnosed in the community. In 2010, around 1.9% of the people in United States age 40 and older. Additionally, technological advancements in the field of ophthalmology and increasing initiatives regarding the awareness of Glaucoma to make aware of the deadly disease. For instance, in March 2020, theme named sneak thief of sight has been hosted at Gandhi Thidal as part of a campaign to raise glaucoma awareness. In India, only 5-10% of the people are aware of the disease. However, stringent approval process coupled with the side effects associated with the products are the major factors hampering the growth of the market.
Study Period
2024-2030Base Year
2023CAGR
6.98%Largest Market
North AmericaFastest Growing Market
Europe
Glaucoma is the second leading cause of blindness, globally and is the top cause of irreversible blindness in the world. For instance, According to WHO estimates, more than 60 million patients are suffering from glaucoma worldwide, as per 2019 statistics. According to the Glaucoma Research Foundation, in the United States, more than 120,000 patients are blind from glaucoma. Thus, owing to the increasing cases of glaucoma the market is anticipated to witness high growth over the forecast period.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2022 |
US$ 7.91 billion |
Market Size in 2029 |
US$ 13.53 billion |
Market CAGR |
6.98% |
By Indication |
|
By Drug Class |
|
By Sales Channel |
|
By Region |
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
|
Download Free Sample Report
2022 is the base year and 2029 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Glaucoma Treatment Market size was valued at US$ 7.91 billion in 2022 and is projected to reach US$ 13.53 billion by 2029, growing at a CAGR of 6.98% from 2023 to 2029.
1.Executive Summary |
2.Global Glaucoma Treatment Market Introduction |
2.1.Global Glaucoma Treatment Market - Taxonomy |
2.2.Global Glaucoma Treatment Market - Definitions |
2.2.1.Indication |
2.2.2.Drug Class |
2.2.3.Sales Channel |
2.2.4.Region |
3.Global Glaucoma Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Glaucoma Treatment Market Analysis, 2018-2022 and Forecast 2023-2029 |
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Glaucoma Treatment Market By Indication, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
5.1. Open Angle Glaucoma |
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Closed Angle Glaucoma |
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Congenital Glaucoma |
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Secondary Glaucoma |
5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Others |
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
6.Global Glaucoma Treatment Market By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
6.1. Alpha Agonist |
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Beta Blockers |
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Prostaglandin Analogs |
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Carbonic Anhydrase Inhibitors |
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Others |
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7.Global Glaucoma Treatment Market By Sales Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Sales |
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Glaucoma Treatment Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Glaucoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
9.1. Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Open Angle Glaucoma |
9.1.2.Closed Angle Glaucoma |
9.1.3.Congenital Glaucoma |
9.1.4.Secondary Glaucoma |
9.1.5.Others |
9.2. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Alpha Agonist |
9.2.2.Beta Blockers |
9.2.3.Prostaglandin Analogs |
9.2.4.Carbonic Anhydrase Inhibitors |
9.2.5.Others |
9.3. Sales Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Online Sales |
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Glaucoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
10.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Open Angle Glaucoma |
10.1.2.Closed Angle Glaucoma |
10.1.3.Congenital Glaucoma |
10.1.4.Secondary Glaucoma |
10.1.5.Others |
10.2. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Alpha Agonist |
10.2.2.Beta Blockers |
10.2.3.Prostaglandin Analogs |
10.2.4.Carbonic Anhydrase Inhibitors |
10.2.5.Others |
10.3. Sales Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Online Sales |
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
10.4.7. |
11.Asia Pacific (APAC) Glaucoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
11.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Open Angle Glaucoma |
11.1.2.Closed Angle Glaucoma |
11.1.3.Congenital Glaucoma |
11.1.4.Secondary Glaucoma |
11.1.5.Others |
11.2. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Alpha Agonist |
11.2.2.Beta Blockers |
11.2.3.Prostaglandin Analogs |
11.2.4.Carbonic Anhydrase Inhibitors |
11.2.5.Others |
11.3. Sales Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Online Sales |
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Glaucoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
12.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Open Angle Glaucoma |
12.1.2.Closed Angle Glaucoma |
12.1.3.Congenital Glaucoma |
12.1.4.Secondary Glaucoma |
12.1.5.Others |
12.2. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Alpha Agonist |
12.2.2.Beta Blockers |
12.2.3.Prostaglandin Analogs |
12.2.4.Carbonic Anhydrase Inhibitors |
12.2.5.Others |
12.3. Sales Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Online Sales |
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Glaucoma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
13.1. Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Open Angle Glaucoma |
13.1.2.Closed Angle Glaucoma |
13.1.3.Congenital Glaucoma |
13.1.4.Secondary Glaucoma |
13.1.5.Others |
13.2. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Alpha Agonist |
13.2.2.Beta Blockers |
13.2.3.Prostaglandin Analogs |
13.2.4.Carbonic Anhydrase Inhibitors |
13.2.5.Others |
13.3. Sales Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Online Sales |
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Novartis AG |
14.2.2.Akorn, Incorporated |
14.2.3.Inotek Pharmaceuticals |
14.2.4.Aerie Pharmaceuticals Inc. |
14.2.5.Merck & Co., Inc. |
14.2.6.Pfizer Inc |
14.2.7.Abbvie Inc. (Allergan Plc) |
14.2.8.Santen Pharmaceutical Co., Ltd. |
14.2.9.Bausch Health (Bausch & Lomb Incorporated) |
14.2.10.Teva Pharmaceuticals |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players